Key result
Mitochondrial dysfunction is implicated in pathological cardiac hypertrophy, and targeting mitochondrial energetics, dynamics, and mitophagy presents potential therapeutic strategies.
Why the study?
Mitochondrial dysfunction is implicated in pathological cardiac hypertrophy, but a comprehensive synthesis of mitochondrial alterations and mitochondria-targeting therapeutic strategies was needed.
This review highlights the critical role of mitochondrial morphological and functional alterations in pathological cardiac hypertrophy, suggesting mitochondria-targeted strategies as potential therapies.
Mitochondrial strategies should not yet change hypertrophy practice; leaves open validation in prospective trials.
Cardiac hypertrophy, a stereotypic cardiac response to increased workload, ultimately progresses to severe contractile dysfunction and uncompensated heart failure without appropriate intervention. Sustained cardiac overload inevitably results in high energy consumption, thus breaking the balance between mitochondrial energy supply and cardiac energy demand. In recent years, accumulating evidence has indicated that mitochondrial dysfunction is implicated in pathological cardiac hypertrophy. The significant alterations in mitochondrial energetics and mitochondrial proteome composition, as well as the altered expression of transcripts that have an impact on mitochondrial structure and function, may contribute to the initiation and progression of cardiac hypertrophy. This article presents a summary review of the morphological and functional changes of mitochondria during the hypertrophic response, followed by an overview of the latest research progress on the significant modulatory roles of mitochondria in cardiac hypertrophy. Our article is also to summarize the strategies of mitochondria-targeting as therapeutic targets to treat cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2022) conducted a review in Pathological Cardiac Hypertrophy. Mitochondria-targeted therapies was evaluated. Mitochondrial dysfunction is implicated in pathological cardiac hypertrophy, and targeting mitochondrial energetics, dynamics, and mitophagy presents potential therapeutic strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: